Page last updated: 2024-12-06

n-hydroxypiperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

N-hydroxypiperidine is a cyclic hydroxylamine that is used as a building block in the synthesis of various organic compounds. It can be synthesized by the reaction of piperidine with hydrogen peroxide. N-hydroxypiperidine has been shown to exhibit biological activity, including antioxidant and neuroprotective effects. It is studied for its potential applications in medicinal chemistry, such as in the development of new drugs for the treatment of neurological disorders. N-hydroxypiperidine is also of interest in the field of materials science, where it has been used to synthesize polymers with unique properties.'

Cross-References

ID SourceID
PubMed CID20935
CHEMBL ID277887
SCHEMBL ID1360
SCHEMBL ID10519419
MeSH IDM0172544

Synonyms (33)

Synonym
einecs 225-362-9
piperidin-1-ol
piperidine, 1-hydroxy-
brn 0102726
n-hydroxypiperidine
1-hydroxypiperidine, >=96.0% (gc)
inchi=1/c5h11no/c7-6-4-2-1-3-5-6/h7h,1-5h2
lkpfbgkzccbzdk-uhfffaoysa-
1-hydroxypiperidine
CHEMBL277887
STK331484
1-hydroxy-piperidine
4801-58-5
hydroxypiperidine
piperidinol
unii-9anq5db3a2
5-20-03-00478 (beilstein handbook reference)
9anq5db3a2 ,
1-piperidinol
AKOS015897997
SCHEMBL1360
DTXSID9063611
piperidol
n-hydroxy-piperidine
SCHEMBL10519419
mfcd00038048
FT-0720141
AS-38272
Q6951371
A871996
CS-W016646
EN300-6472910
SY240047
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30384Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-8-10e-41985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30391Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30524Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -8 - 10 E -4 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.89 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]